Dr. Yutaka Matsuoka


Academic Degree(s)






Current Position

Chief, Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan


Professional Experience

  • Executive Director, Japan Supportive, Palliative and Psychosocial Oncology Group (2015-present)
  • Project Leader of Clinical Research Track Program, National Center of Neurology and Psychiatry (2009-2015)


Education & Training

  • MD, The Jikei University School of Medicine, Tokyo Japan (1987-1993)
  • PhD, Hiroshima University, Hiroshima Japan (1995-2003)



  • Kaneko Award, Japanese Society of General Hospital Psychiatry (2016) MBI International Symposium Overseas Travel Award (2014)
  • Young Researcher Award, Pacific Rim College of Psychiatrists (2012)
  • Society Award, Japan Psycho-Oncology Society (2010)
  • Otsuka Award, Japan Society for Lipid Nutrition (2010)


Research Grants

  • JSPS KAKENHI Grant-in-Aid for Young Scientists B (2004.4-2007.3)
  • CREST, JST (2007.10-2014.3)
  • Intramural Research Grant for Neurological and Psychiatric Disorders from NCNP (2012.4-2018.3)
  • Grants from Pfizer Health Research Foundation (2014.12-2015.11) and SENSHIN Medical Research Foundation (2016.12-2017.11)


Committee & Membership

  • President, 26th Annual Meeting of Japan Society for Lipid Nutrition (2017)
  • Director, Japan Society for Lipid Nutrition (2013-present)
  • VP, International Society for Nutritional Psychiatry Research (2013-present)


Selected Publication

  • Yamashita A, Noguchi H, Hamazaki K, Sato Y, Narisawa T, Kawashima Y, Usuki M, Nishi D, Yoshimasu H, Horikawa N, Matsuoka YJ: Serum polyunsaturated fatty acids and risk of psychiatric disorder after acute coronary syndrome: a prospective cohort study. J Affective Disorders August 15, 2017; 218:306-312
  • Matsuoka YJ, Hamazaki K, Nishi D, Hamazaki T: Change in blood levels of eicosapentaenoic acid and posttraumatic stress symptom: A secondary analysis of data from a placebo-controlled trial of omega-3 supplements J Affective Disorders 2016; 205:289-291
  • Matsumura K, Noguchi H, Nishi D, Hamazaki K, Hamazaki T, Matsuoka YJ: Effects of omega-3 polyunsaturated fatty acids on psychophysiological symptoms of post-traumatic stress disorder in accident survivors: a randomized, double-blind, placebo-controlled trial. J Affective Disorders 2016 May 30. pii: S0165-0327(16)30239-7
  • Matsuoka Y, Nishi D, Hamazaki K, Yonemoto N, Matsumura K, Noguchi H, Hashimoto K, Hamazaki T: Docosahexaenoic acid for selective prevention of posttraumatic stress disorder among severely injured patients: A randomized, placebo-controlled trial. J Clin Psychiatry 2015;76(8):e1015–e1022
  • Matsuoka Y, Nishi D, Tanima Y, Itakura M, Kojima M, Hamazaki K, Noguchi H, Hamazaki T: Serum pro-BDNF/BDNF as a treatment biomarker for response to docosahexaenoic acid in traumatized people vulnerable to developing psychological distress: A randomized controlled trial. Transl Psychiatry 2015: 5; e596
  • Hashimoto M, Maekawa M, Katakura M, Hamazaki K, Matsuoka Y: Possibility of polyunsaturated fatty acids for the prevention and treatment of neuropsychiatric illnesses. J Pharmacol Sci 124(3):294-300, 2014
  • Matsuoka Y, Nishi D, Hamazaki K: Serum levels of polyunsaturated fatty acids and the risk of posttraumatic stress disorder. Psychother Psychosom 82(6):408-410, 2013
  • Nishi D, Koido Y, Nakaya N, Sone T, Noguchi H, Hamazaki K, Hamazaki T, Matsuoka Y: Fish oil for attenuating posttraumatic stress symptoms among rescue workers after the Great East Japan Earthquake: A randomized controlled trial. Psychother Psychosom 81:315-317, 2012
  • Matsuoka Y, Nishi D, Yonemoto N, Hamazaki K, Hamazaki T, Hashimoto K: Potential role of brain-derived neurotrophic factor in omega-3 fatty acid supplementation to prevent posttraumatic distress after accidental injury: An open-label pilot study. Psychother Psychosom 80:310-312, 2011
  • Matsuoka Y, Nishi D, Yonemoto N, Hamazaki K, Hashimoto K, Hamazaki T: Omega-3 fatty acids for secondary prevention of posttraumatic stress disorder after accidental injury: An open-label pilot study. J Clin Psychopharmacol 30(2):217-219, 2010


SSCI/SCI: 77 (first author:21, Jcorresponding author: 37)

Impact Factor>5: 17 papers (JIF>10: 7 papers)